213 related articles for article (PubMed ID: 30633746)
21. Delayed Antitoxin Treatment of Two Adult Patients with Botulism after Cosmetic Injection of Botulinum Type A Toxin.
Fan KL; Wang YL; Chu G; Leung LP
J Emerg Med; 2016 Dec; 51(6):677-679. PubMed ID: 27687174
[TBL] [Abstract][Full Text] [Related]
22. Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine.
Machamer JB; Vazquez-Cintron EJ; O'Brien SW; Kelly KE; Altvater AC; Pagarigan KT; Dubee PB; Ondeck CA; McNutt PM
Mol Med; 2022 Jun; 28(1):61. PubMed ID: 35659174
[TBL] [Abstract][Full Text] [Related]
23. Development of immunodetection system for botulinum neurotoxin serotype E.
Sarita R; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Indian J Med Res; 2018 Jun; 147(6):603-610. PubMed ID: 30168493
[TBL] [Abstract][Full Text] [Related]
24. Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin.
Yu PA; Lin NH; Mahon BE; Sobel J; Yu Y; Mody RK; Gu W; Clements J; Kim HJ; Rao AK
Clin Infect Dis; 2017 Dec; 66(suppl_1):S57-S64. PubMed ID: 29293928
[TBL] [Abstract][Full Text] [Related]
25. A Rabbit Model for the Evaluation of Drugs for Treating the Chronic Phase of Botulism.
Torgeman A; Diamant E; Dor E; Schwartz A; Baruchi T; Ben David A; Zichel R
Toxins (Basel); 2021 Sep; 13(10):. PubMed ID: 34678971
[TBL] [Abstract][Full Text] [Related]
26. Studying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model.
Torgeman A; Schwartz A; Diamant E; Baruchi T; Dor E; Ben David A; Pass A; Barnea A; Tal A; Rosner A; Rosen O; Zichel R
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115749
[TBL] [Abstract][Full Text] [Related]
27. Pediatric Botulism and Use of Equine Botulinum Antitoxin in Children: A Systematic Review.
Griese SE; Kisselburgh HM; Bartenfeld MT; Thomas E; Rao AK; Sobel J; Dziuban EJ
Clin Infect Dis; 2017 Dec; 66(suppl_1):S17-S29. PubMed ID: 29293924
[TBL] [Abstract][Full Text] [Related]
28. Clinical recovery and circulating botulinum toxin type F in adult patient.
Sobel J; Dill T; Kirkpatrick CL; Riek L; Luedtke P; Damrow TA
Emerg Infect Dis; 2009 Jun; 15(6):969-71. PubMed ID: 19523306
[TBL] [Abstract][Full Text] [Related]
29. Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin.
Fagan RP; Neil KP; Sasich R; Luquez C; Asaad H; Maslanka S; Khalil W
Clin Infect Dis; 2011 Nov; 53(9):e125-8. PubMed ID: 21896700
[TBL] [Abstract][Full Text] [Related]
30. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.
Pellett S; Tepp WH; Bradshaw M; Kalb SR; Dykes JK; Lin G; Nawrocki EM; Pier CL; Barr JR; Maslanka SE; Johnson EA
mSphere; 2016; 1(1):. PubMed ID: 27303710
[TBL] [Abstract][Full Text] [Related]
31. Clinical analysis of 86 botulism cases caused by cosmetic injection of botulinum toxin (BoNT).
Bai L; Peng X; Liu Y; Sun Y; Wang X; Wang X; Lin G; Zhang P; Wan K; Qiu Z
Medicine (Baltimore); 2018 Aug; 97(34):e10659. PubMed ID: 30142749
[TBL] [Abstract][Full Text] [Related]
32. Immunologic and Protective Properties of Subunit- vs. Whole Toxoid-Derived Anti-Botulinum Equine Antitoxin.
Ben David A; Barnea A; Torgeman A; Diamant E; Dor E; Schwartz A; Rosen O; Caspi N; Saraf M; Lerer E; Adar Y; Lupo E; Toister E; Zichel R
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146601
[TBL] [Abstract][Full Text] [Related]
33. Development of vaccines for prevention of botulism.
Byrne MP; Smith LA
Biochimie; 2000; 82(9-10):955-66. PubMed ID: 11086225
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Antitoxin Therapy in Treating Patients With Foodborne Botulism: A Systematic Review and Meta-analysis of Cases, 1923-2016.
O'Horo JC; Harper EP; El Rafei A; Ali R; DeSimone DC; Sakusic A; Abu Saleh OM; Marcelin JR; Tan EM; Rao AK; Sobel J; Tosh PK
Clin Infect Dis; 2017 Dec; 66(suppl_1):S43-S56. PubMed ID: 29293927
[TBL] [Abstract][Full Text] [Related]
35. Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.
Yu YZ; Zhang SM; Wang WB; Du Y; Zhu HQ; Wang RL; Zhou XW; Lin JB; Wang S; Yu WY; Huang PT; Sun ZW
Biochimie; 2010 Oct; 92(10):1315-20. PubMed ID: 20600570
[TBL] [Abstract][Full Text] [Related]
36. A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice.
Fan Y; Lou J; Tam CC; Wen W; Conrad F; Leal da Silva Alves P; Cheng LW; Garcia-Rodriguez C; Farr-Jones S; Marks JD
Toxins (Basel); 2023 Apr; 15(5):. PubMed ID: 37235351
[TBL] [Abstract][Full Text] [Related]
37. Equine botulinum antitoxin for the treatment of infant botulism.
Vanella de Cuetos EE; Fernandez RA; Bianco MI; Sartori OJ; Piovano ML; Lúquez C; de Jong LI
Clin Vaccine Immunol; 2011 Nov; 18(11):1845-9. PubMed ID: 21918119
[TBL] [Abstract][Full Text] [Related]
38. A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.
Maslanka SE; Lúquez C; Dykes JK; Tepp WH; Pier CL; Pellett S; Raphael BH; Kalb SR; Barr JR; Rao A; Johnson EA
J Infect Dis; 2016 Feb; 213(3):379-85. PubMed ID: 26068781
[TBL] [Abstract][Full Text] [Related]
39. Challenges in searching for therapeutics against Botulinum Neurotoxins.
Pirazzini M; Rossetto O
Expert Opin Drug Discov; 2017 May; 12(5):497-510. PubMed ID: 28271909
[TBL] [Abstract][Full Text] [Related]
40. An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E.
Li M; Lee D; Obi CR; Freeberg JK; Farr-Jones S; Tomic MT
PLoS One; 2018; 13(5):e0197011. PubMed ID: 29746518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
